

RESEARCH

Open Access



Hypoxia-associated circDENND2A promotes glioma aggressiveness by sponging miR-625-5p

Hui Su^{1,2}, Defei Zou^{1,2}, Yikun Sun³ and Yiwu Dai^{1,2*}

* Correspondence: dddywww@163.com

¹Department of Neurosurgery, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, People's Republic of China
²Department of Neurosurgery, Bayi Brain Hospital, PLA Army General Hospital, Beijing, People's Republic of China

Full list of author information is available at the end of the article

Abstract

Background: As a newfound type of non-coding RNA, circular RNAs (circRNAs) are involved in various physiological and pathological processes via regulation of gene expression. Increasing evidence shows that aberrantly expressed circRNAs play a crucial role in the initiation and progression of many tumors. However, the functions of different circRNAs in gliomas remain elusive.

Methods: The levels of circRNAs, miRNAs, and mRNAs were quantified by qPCR. The interaction between circDENND2A and miR-625-5p was determined by luciferase reporter and pull-down assays. The migratory and invasive capabilities of glioma cells were examined by wound healing and Transwell assays. Immunohistochemistry was performed to analyze the HIF1 α level in glioma tissues.

Results: We predicted circDENND2A (has_circ_0002142) to be a hypoxia-responsive circRNA in glioma via a bioinformatic analysis. We found that hypoxia induced the expression of circDENND2A, which promoted migration and invasion of glioma cells. To understand the behaviors of circDENND2A in glioma, we studied the putative miRNAs targeted by circDENND2A and identified circDENND2A as an efficient sponge of miR-625-5p in glioma cells. Phenotype experiments verified that circDENND2A was required for the hypoxia-induced migration and invasion of glioma cells and that this occurred by sponging of miR-625-5p. Notably, glioma tissues overexpressing HIF1 α exhibited a high expression of circDENND2A as well as a low expression of miR-625-5p. circDENND2A was negatively correlated with miR-625-5p.

Conclusion: circDENND2A is required for the hypoxia-induced malignancy of glioma cells and functions by sponging miR-625-5p.

Keywords: circDENND2A, miR-625-5p, Glioma, Hypoxia, Migration, Invasion

Introduction

Glioma is the most prevalent and malignant tumor of the central nervous system, originating from glial cells [1]. The highly invasive and infiltrative characteristics of glioma confer its incurability and mortality [2]. Despite many potential treatments having been applied in glioma, the outcomes are unfavorable due to this cancer's extensive growth patterns [3]. Therefore, a detailed understanding of the mechanisms underlying glioma pathology is urgently needed for novel therapeutic approaches.

Circular RNA (circRNA) belongs to the larger category of non-coding RNA. circRNAs are characterized by covalently closed-loop structures with no 5' to 3' polarity and no



polyadenylated tail [4]. Their circular structure confers strong resistance to RNase R and a stable existence in cells [5]. Generally, circRNA regulates gene transcription and expression by serving as a sponge of miRNA [6, 7]. Therefore, the circRNA-miRNA-mRNA regulatory axis has been widely explored to illustrate the biological functions of circRNA [8]. Increasing evidence suggests that circRNAs participate in a variety of physiological and pathological processes [9]. As critical regulators in the development and progression of several malignancies, dysregulated circRNAs promote tumor proliferation, migration, and invasion [10–12]. However, little is known about the roles of circRNAs in glioma development, especially under hypoxic conditions.

MicroRNA (miRNA) is a class of non-coding small RNAs that regulates gene expression at the post-transcriptional level [13]. Abnormal expression profiles of miRNAs have been observed in a wide range of human cancers, including glioma [14–16]. As a tumor suppressor, miR-625 is downregulated in gastric cancer, breast cancer, and hepatocellular carcinoma [17–19]. These studies indicated that the decreased expression of miR-625 was closely associated with tumor growth, invasiveness, and metastasis, and also showed that it predicted high malignancy and poor prognosis. The levels of miR-625 have been consistently found to be inversely correlated with glioma grades. miR-625 inhibits the proliferation and increases the chemosensitivity of glioma cells [20]. However, the reason behind miR-625's effects on glioma is still unknown.

In the present study, we found that hsa_circ_0002142 (circDENND2A), a circRNA derived from the *DENND2A* gene, was induced by hypoxia in glioma cells, and the circDENND2A possessed a potent ability to sponge miR-625-5p. Phenotype experiments indicated that the circDENND2A was indispensable for the hypoxia-induced migration and invasion of glioma cells by sponging miR-625-5p. Furthermore, clinical analysis confirmed the negative correlation between circDENND2A and miR-625-5p in glioma tissues.

Materials and methods

Cell culture and treatment

The normal human astrocyte line SVGp12 and two human glioma cell lines, U87MG and A172, were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco's Modified Eagle's medium (DMEM) with 10% fetal bovine serum (Gibco, Waltham, MA, USA) at 37 °C under an atmosphere of 5% CO₂. In hypoxia experiments, cells were cultured in 1% O₂, 5% CO₂, and 94% N₂. Plasmids, miRNA, and small interfering RNAs (siRNAs) were transfected into U87MG cells with Lipofectamine™ 3000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol.

Constructions and reagents

CircDENND2A overexpression plasmid and siRNA, miR-625-5p mimic, and inhibitor were synthesized by GenePharma (Shanghai, China). The sequences of circDENND2A siRNA, miR-625-5p mimic, and inhibitor are shown in Additional file 1: Table S1.

Quantitative real-time PCR (qPCR) for circRNA, mRNA, and miRNA

Total RNA was extracted using the RNAiso™ Plus reagent (Takara, Otsu, Japan). For RNase R digestion, 5 mg total RNA was treated for 15 min at 37 °C with 5 U/mg RNase

R. Then, qPCR for circRNA and mRNA was performed with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA). miRNA-specific quantitative PCR was carried out with TaqMan MicroRNA Assay primers (Applied Biosystems). circRNA/mRNA and miRNA were individually normalized to β -actin and U6. The primer sequences of the circRNAs and mRNAs are shown in Additional file 1: Table S1.

Fluorescence in situ hybridization (FISH)

DNA oligo probes labeled with FITC for circDENND2A were synthesized by GenePharma (Shanghai, China). U87MG cells in the logarithmic phase were washed with PBS and fixed in 4% paraformaldehyde. After permeabilization with PBS containing 0.5% Triton X-100 for 5 min at 4 °C, the cells were incubated in hybridization buffer (40% formamide, 10% dextran sulfate, 1 × Denhardt's solution, 4 × SSC, 10 mM DDT, 1 mg/mL yeast transfer RNA, and 1 mg/mL sheared salmon sperm DNA) with the probes specific to circDENND2A at 42 °C overnight. Nuclei were stained with 4, 6-diamidino-2-phenylindole (DAPI). Images were acquired using a fluorescence microscope.

Wound healing assay

U87MG cells were seeded in six-well plates. After transfection for 24 h, the monolayer was gently scratched with a pipette tip and then washed with phosphate-buffered saline (PBS) to remove detached cells. Each well was re-loaded with serum-free medium, and cells were cultured for additional 48 h, when images of the scratched monolayers were captured on a microscope. The wounds were evaluated using ImageJ.

Transwell assay

The invasive capability of U87MG cells was evaluated in Boyden chambers with Matrigel according to the manufacturer's protocol (Invitrogen). The 8-mm-porosity polycarbonate membrane was covered with 200 μ L of serum-free medium containing 1×10^5 cells per well. The plates were then incubated with 10% fetal bovine serum (FBS) medium for 48 h at 37 °C in a 5% CO₂ incubator. The invading cells on the bottom surface of the filter were fixed, stained, and counted using optical microscopy.

Pull-down assay

U87MG cells were transfected with biotinylated miR-625-5p mimics or control miRNA and harvested at 48 h after transfection. The biotin-labeled miRNA was pulled down by incubating the cell lysates with Dynabeads™ M-270 Streptavidin Beads (Invitrogen). The bound RNA was purified using a PureLink™ RNA Mini Kit (Invitrogen) for analysis. The abundance of circDENND2A was evaluated by qPCR analysis.

Luciferase reporter assay

pGL3-circDENND2A was constructed based on pGL3-control, and pGL3-circDENND2A with a mutant miR-625-5p binding site was subcloned from wild-type pGL3-circDENND2A. U87MG cells were plated onto 24-well plates the day before transfection. The cells were co-transfected with 0.5 μ g of wild-type or mutant pGL3-circDENND2A, 0.02 μ g of pRL-TK Renilla luciferase reporter plasmids

(Promega, Madison, WI, USA), and miR-625-5p mimics. Luciferase activity was measured by a Dual-Luciferase Reporter Assay System (Promega).

Immunohistochemistry (IHC)

In total, 180 glioma cases came from the National Human Genetic Resources Sharing Service Platform (No. 2005DKA21300), and informed consent was obtained from all of the patients. The study was approved by the Ethics Committee of Chinese PLA General Hospital and Shanghai Outdo Biotech Company (Shanghai, China). All of the specimens were fixed in 10% neutral formalin, embedded in paraffin, and cut into 4- μ m sections for immunohistochemical staining. The EnVision™ two-step method was used (DAKO, Hamburg, Germany), along with an antibody against HIF1 α . To estimate the score for each slide, at least 10 individual fields at 200 \times were chosen, and 100 cancer cells were counted in each field. The immunostaining intensity was divided into four grades: 0, no expression; 1, mildly positive; 2, moderately positive; and 3, markedly positive. The proportion of positive-staining cells was divided into five grades: 0, < 10%; 1, 11–25%; 2, 26–50%; 3, 51–75%; and 4, > 75%. The staining results were assessed and confirmed by two independent investigators blinded to the clinical data. The percentage of positivity of the tumor cells and the staining intensities were then multiplied in order to generate the IHC score, and graded as 0–6, low expression; and 7–12, high expression.


Statistical analysis

Statistical data analysis was performed using SPSS 22.0 and GraphPad Prism 5.0. The data are reported as the mean \pm SD. A *P* value < 0.05 was considered statistically significant. The two-tailed Student's *t* test and analysis of variance (ANOVA) were used to determine significant differences. A χ^2 test was used to compare the clinicopathological features of glioma patients with HIF1 α expression. The Pearson test was used in analyzing the correlations.

Results

CircCENND2A is a hypoxia-responsive circRNA in glioma cells

In order to profile the hypoxia-associated circRNAs, we compared the differentially expressed circRNA profiles between glioma and normal tissues (GSE86202) [21] with the differentially expressed mRNA profiles in U87MG cells between hypoxia and normoxia (GSE45301) [22]. As shown in Fig. 1a, expression changes of 12 circRNAs in glioma tissues and their host genes in hypoxia were confirmed, suggesting potential hypoxia-associated circRNAs in glioma. Notably, the expression levels of only one circRNA (circDENND2A) and its host gene (DENND2A) were found to be upregulated. To identify the circRNAs involved in response to hypoxia, we examined the levels of the 12 circRNAs in hypoxic or normoxic U87MG cells. Two circRNAs, most noticeably circDENND2A, were significantly increased, and four circRNAs showed decreases in the U87MG cells treated with hypoxia (Fig. 1b). We found that the hypoxia-induced DENND2A circRNA but not mRNA was resistant to RNase R exonuclease, which verified that circDENND2A was induced by hypoxia (Fig. 1c). In addition, fluorescence in situ hybridization (FISH) also indicated the hypoxia-induced accumulation of



circDENND2A in the cytoplasm of U87MG cells (Fig. 1d). Notably, the expression of circDENND2A was induced by hypoxia in two glioma cell lines, U87MG and A172, but not in the normal human astrocyte line SVGp12 (Fig. 1e).

CircDENND2A contributes to the hypoxia-induced migration and invasion of glioma cells

To further reveal the role of circDENND2A in glioma development, we examined the phenotype of glioma cells with knockdown or overexpression of circDENND2A. The results of wound healing and Transwell assays showed that hypoxia promoted the migration and invasion of U87MG and A172 cells, while knockdown of circDENND2A undermined the hypoxia-induced aggressive characteristics (Fig. 2a and b). In contrast, knockdown of circDENND2A had no effect on the phenotypes of glioma cells under normoxic conditions (Fig. 2a and b). Like hypoxia, overexpression of circDENND2A strengthened the migratory and invasive capabilities of U87MG cells (Fig. 2c and d).

CircDENND2A functions as an efficient miR-625-5p sponge in glioma cells


To explore the mechanisms underlying the positive effect of circDENND2A on glioma progression, we predicted the putative miRNAs sponged by circDENND2A via Circular RNA Interactome (<https://circinteractome.nia.nih.gov/>). Eleven miRNAs were screened out based on the context + score percentile (> 90) (Fig. 3a). After cells were transfected with circDENND2A, six miRNAs were significantly decreased, among which the most obvious one was miR-625-5p (Fig. 3b). Furthermore, pull-down assays indicated a much stronger enrichment of circDENND2A in the biotin-labeled miR-625-5p-captured fraction than in the negative control (Fig. 3c). A luciferase reporter assay showed that miR-625-5p suppressed the activity of a reporter plasmid containing wild-type circDENND2A but failed to do so when a circDENND2A plasmid with a mutant miR-625-5p-binding site was used. This suggested that there is an interaction between wild-type circDENND2A and miR-625-5p (Fig. 3d). Hypoxia reduced the level of miR-625-5p in U87MG and A172 cells, but this miRNA was increased by knockdown of circDENND2A. However, neither hypoxia nor circDENND2A knockdown altered the level of miR-625-5p in SVGP12 cells (Fig. 3e). As a validated target of miR-625-5p [20], AKT2 was inhibited by miR-625-5p transfection. However, overexpressed circDENND2A blocked the effect of miR-625-5p (Fig. 3f). In summary, circDENND2A can regulate the expression levels of some downstream genes by sponging miR-625-5p.

CircDENND2A enhances the migration and invasion of glioma cells via sponging of miR-625-5p


To determine whether miR-625-5p is involved in the malignancy driven by circDENND2A, we studied the phenotypes of glioma cells with knockdown of circDENND2A or miR-625-5p. As shown in Fig. 4a and b, silencing of miR-625-5p restored the hypoxia-induced migration and invasion attenuated by circDENND2A knockdown in U87MG and A172 cells. Therefore, circDENND2A may act as a potent inhibitor of the tumor suppressor miR-625-5p to promote glioma progression.

The circDENND2A/miR-625-5p pathway is related to HIF1 α in glioma tissues

Overexpression of HIF1 α leads to tumor progression and poor prognosis in patients with glioma. In this study, an analysis of clinical relevance indicated that the levels of HIF1 α were positively associated with WHO grades in 180 glioma cases (Table 1), which was consistent with previous reports [23]. HIF1 α is a specific marker for hypoxia. We analyzed the relation between HIF1 α and circDENND2A or miR-625-5p. With




immunohistochemistry, 35 frozen glioma tissues from the 180 cases were separated into a high HIF1 α -expression group (IHC score: 0–6) and a low-expression group (IHC score: 7–12) (Fig. 5a). The high-expression group exhibited a higher level of circDENND2A but a lower level of miR-625-5p than the low-expression group (Fig. 5b and c). Further analysis



indicated a negative correlation between circDENND2A and miR-625-5p in glioma (Fig. 5d).

Discussion

Glioma is characterized by extensive tissue hypoxia due to intratumoral necrosis. A hypoxic microenvironment has been thought to be a driving force in glioma, which develops an aggressive tumor phenotype by displaying high levels of metastasis and losing apoptotic potential [24]. Recent studies have described hypoxia as an essential environmental condition for the maintenance of glioma stem cells (GSCs), the subpopulation of glioma cells leading to resistance to chemotherapy and radiation [25]. As circRNA has attracted more attention in recent years, several circRNAs have been demonstrated in the development of glioma [26]. However, the interaction between



hypoxia and circRNA in glioma remains unknown. Previous work first identified hypoxia-regulated circRNAs in endothelial cells [27]. On the basis of this discovery, Yang et al. found that the circRNA cZNF292 contributed to glioma tube formation via the Wnt/ β -catenin signaling pathway [28]. Here, we have discovered a hypoxia-induced circRNA, circDENND2A, by analyzing the profiles of differentially-expressed circRNAs in glioma tissues and mRNAs in hypoxic glioma cells. Further investigation confirmed that the upregulated circDENND2A was necessary for increased migration and invasion of hypoxic glioma cells. Therefore, we hypothesized that circDENND2A may display a pivotal role in the glioma metastasis induced by hypoxia.


Table 1 Correlation of the expression of HIF1 α with clinicopathological features in glioma

	Total	HIF1 α		P
		low	high	
	180	91	89	
Gender				0.5897
male	112	55	57	
female	68	36	32	
Age				0.1287
< 40	80	43	37	
\geq 40	100	48	52	
Tumor location				0.9403
Temporal	56	26	30	
Frontal	54	28	26	
Parietal	12	5	7	
Ventricle	11	6	5	
Occipital	9	5	4	
Others	38	21	17	
WHO grade				< 0.0001*
I	26	14	12	
II	85	54	31	
III	42	20	22	
IV	25	3	22	
Unknown	2	0	2	

*P < 0.05

Hypoxia-inducible factor 1 α (HIF1 α) is a hallmark of hypoxia. It activates the transcription of downstream oncogenes containing hypoxia-responsive elements (HREs), thereby regulating tumor metabolism and metastasis [29]. Overexpression of HIF1 α in surgically resected glioma tissues has been found to have a positive correlation with invasiveness and poor survival [30]. In the present study, we explored the association between HIF1 α and circDENND2A or miR-625-5p. Glioma tissues with overexpressed HIF1 α showed high levels of circDENND2A and low levels of miR-625-5p. Liang et al. reported that in breast cancer cells, HIF1 α was crucial for the upregulation of circDENND4C under hypoxic conditions [31]. However, the crosstalk between HIF1 α and the circDENND2A/miR-625-5p pathway in glioma still needs more investigation.

In this work, circDENND2A was shown to enhance the migration and invasion of glioma cells by sponging miR-625-5p, indicating that miR-625-5p served as a tumor suppressor in glioma. The mechanisms underlying the anti-tumor function of miR-625-5p in different cancer types had been demonstrated in previous studies. In breast cancer, miR-625-5p suppressed cell proliferation and migration by targeting HMGA1 [18]. In another report, miR-625-5p targeted IGF2BP1 to inhibit the migration and invasion of hepatocellular carcinoma [19]. Zhang et al. found that miR-625-5p decreased the proliferation and increased the chemosensitivity of glioma via AKT2 [20]. Notably, SOX2 has been validated as a target of miR-625, as it induced migration and invasion in melanoma and esophageal cancer [32, 33]. As an embryonic transcription factor, SOX2 maintains cancer stem cells and drives the epithelial-to-mesenchymal transition (EMT)



[34]. Thus, it will be worthwhile to investigate whether the circDENND2A/miR-625-5p pathway participates in hypoxia-induced stemness and EMT in glioma by regulating SOX2.

In conclusion, our study characterizes a novel hypoxia-associated circRNA, circDENND2A, which enhances the migration and invasion of glioma cells by directly sponging miR-625-5p. Clinical analysis suggested the existence of a circDENND2A/miR-625-5p axis in glioma tissues, which was associated with HIF1 α . Collectively, understanding the mechanism of this interaction may provide us a promising therapeutic target for glioma metastases in hypoxic microenvironments.

Additional file

Additional file 1: Table S1. The sequences of circDENND2A siRNA, miR-625-5p mimic and inhibitor. (DOCX 17 kb)

Abbreviations

circRNA: Circular RNA; EMT: Epithelial-to-mesenchymal transition; GSCs: Glioma stem cells; HIF1 α : Hypoxia-inducible factor 1 α ; HRE: Hypoxia-responsive element; miRNA: MicroRNA

Acknowledgements

Not applicable.

Funding

This work was financially supported by the Natural Science Foundation of China (NSFC-81271391).

Availability of data and materials

Not applicable.

Authors' contributions

YD conceived and designed the experiments. HS and DZ performed the experiments. HS, DZ and YS analyzed the data. YD drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval

All animal procedures were conducted after approval from the Ethics Committee of Chinese PLA General Hospital and Shanghai Outdo Biotech Company.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Neurosurgery, Chinese PLA General Hospital, Medical School of Chinese PLA, Beijing, People's Republic of China. ²Department of Neurosurgery, Bayi Brain Hospital, PLA Army General Hospital, Beijing, People's Republic of China. ³Department of Neurosurgery, The 306th Hospital of PLA, Beijing, People's Republic of China.

Received: 3 November 2018 Accepted: 15 March 2019

Published online: 02 April 2019

References

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol.* 2016;131(6):803–20.
2. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. *CA Cancer J Clin.* 2010;60(3):166–93.
3. Mangiola A, Anile C, Pompucci A, Capone G, Rigante L, De Bonis P. Glioblastoma therapy: going beyond Hercules columns. *Expert Rev Neurother.* 2010;10(4):507–14.
4. Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. *Nat Biotechnol.* 2014;32(5):453–61.
5. Chen LL, Yang L. Regulation of circRNA biogenesis. *RNA Biol.* 2015;12(4):381–8.
6. Rong D, Sun H, Li Z, Liu S, Dong C, Fu K, et al. An emerging function of circRNA-miRNAs-mRNA axis in human diseases. *Oncotarget.* 2017;8(42):73271–81.
7. Bose R, Ain R. Regulation of transcription by circular RNAs. *Adv Exp Med Biol.* 2018;1087:81–94.
8. Zhang XQ, Yang JH. Discovering circRNA-microRNA interactions from CLIP-Seq data. *Methods Mol Biol.* 2018;1724:193–207.
9. Liu J, Liu T, Wang X, He A. Circles reshaping the RNA world: from waste to treasure. *Mol Cancer.* 2017;16(1):58.
10. Yu J, Xu QG, Wang ZG, Yang Y, Zhang L, Ma JZ, et al. Circular RNA cSMARCA5 inhibits growth and metastasis in hepatocellular carcinoma. *J Hepatol.* 2018;68(6):1214–27.
11. Wang K, Sun Y, Tao W, Fei X, Chang C. Androgen receptor (AR) promotes clear cell renal cell carcinoma (ccRCC) migration and invasion via altering the circHIAT1/miR-195-5p/29a-3p/29c-3p/CDC42 signals. *Cancer Lett.* 2017;394:1–12.
12. Zhang J, Liu H, Hou L, Wang G, Zhang R, Huang Y, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. *Mol Cancer.* 2017;16(1):151.
13. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet.* 2004;5(7):522–31.
14. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. *Nature.* 2005;435(7043):834–8.
15. Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, et al. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. *Neuro-oncology.* 2010;12(5):422–33.
16. Bo LJ, Wei B, Li ZH, Wang ZF, Gao Z, Miao Z. Bioinformatics analysis of miRNA expression profile between primary and recurrent glioblastoma. *Eur Rev Med Pharmacol Sci.* 2015;19(19):3579–86.
17. Wang M, Li C, Nie H, Lv X, Qu Y, Yu B, et al. Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. *FEBS Lett.* 2012;586(16):2382–8.
18. Zhou WB, Zhong CN, Luo XP, Zhang YY, Zhang GY, Zhou DX, et al. miR-625 suppresses cell proliferation and migration by targeting HMGA1 in breast cancer. *Biochem Biophys Res Commun.* 2016;470(4):838–44.
19. Zhou X, Zhang CZ, Lu SX, Chen GG, Li LZ, Liu LL, et al. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma. *Oncogene.* 2015;34(8):965–77.
20. Zhang J, Zhang J, Zhang J, Qiu W, Xu S, Yu Q, et al. MicroRNA-625 inhibits the proliferation and increases the chemosensitivity of glioma by directly targeting AKT2. *Am J Cancer Res.* 2017;7(9):1835–49.
21. Yuan Y, Jiaoming L, Xiang W, Yanhui L, Shu J, Maling G, et al. Analyzing the interactions of mRNAs, miRNAs, lncRNAs and circRNAs to predict competing endogenous RNA networks in glioblastoma. *J Neuro-Oncol.* 2018;137(3):493–502.
22. Kucharzewska P, Christianson HC, Welch JE, Svensson KJ, Fredlund E, Ringner M, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. *Proc Natl Acad Sci U S A.* 2013;110(18):7312–7.

23. Zhao S, Jin C, Zhao X, Jin B, Hui L, Zhou W, et al. Expression and clinical significance of ING4 and HIF-1 alpha in brain astrocytoma. *Zhonghua Yi Xue Za Zhi*. 2015;95(43):3533–6.
24. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. *J Neuro-Oncol*. 2009;92(3):317–35.
25. Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, et al. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. *Neuro-oncology*. 2017;19(7):887–96.
26. Song X, Zhang N, Han P, Moon BS, Lai RK, Wang K, et al. Circular RNA profile in gliomas revealed by identification tool UROBORUS. *Nucleic Acids Res*. 2016;44(9):e87.
27. Boeckel JN, Jae N, Heumuller AW, Chen W, Boon RA, Stellos K, et al. Identification and characterization of hypoxia-regulated endothelial circular RNA. *Circ Res*. 2015;117(10):884–90.
28. Yang P, Qiu Z, Jiang Y, Dong L, Yang W, Gu C, et al. Silencing of cZNF292 circular RNA suppresses human glioma tube formation via the Wnt/beta-catenin signaling pathway. *Oncotarget*. 2016;7(39):63449–55.
29. Li Y, Ye D. Cancer therapy by targeting hypoxia-inducible factor-1. *Curr Cancer Drug Targets*. 2010;10(7):782–96.
30. Erpolat OP, Gocun PU, Akmansu M, Ozgun G, Akyol G. Hypoxia-related molecules HIF-1alpha, CA9, and osteopontin: predictors of survival in patients with high-grade glioma. *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]*. 2013;189(2):147–54.
31. Liang G, Liu Z, Tan L, Su AN, Jiang WG, Gong C. HIF1alpha-associated circDENND4C promotes proliferation of breast Cancer cells in hypoxic environment. *Anticancer Res*. 2017;37(8):4337–43.
32. Fang W, Fan Y, Fa Z, Xu J, Yu H, Li P, et al. microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma. *Oncotarget*. 2017;8(8):13253–63.
33. Wang Z, Qiao Q, Chen M, Li X, Wang Z, Liu C, et al. miR-625 down-regulation promotes proliferation and invasion in esophageal cancer by targeting Sox2. *FEBS Lett*. 2014;588(6):915–21.
34. Wuebben EL, Rizzino A. The dark side of SOX2: cancer - a comprehensive overview. *Oncotarget*. 2017;8(27):44917–43.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

